LUXIQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUXIQ (LUXIQ).
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Metabolized in the skin via ester hydrolysis and further metabolized in the liver; systemic absorption is minimal when applied topically. |
| Excretion | Renal: 30% unchanged; biliary/fecal: 70% as metabolites. |
| Half-life | Terminal half-life: 3-5 hours; in renal impairment may extend to 8 hours. |
| Protein binding | >99% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.7 L/kg; indicates distribution into total body water. |
| Bioavailability | Topical: minimal systemic absorption (<1%) with intact skin; increased with damaged skin up to 5%. |
| Onset of Action | Topical: within 12 hours for plaque psoriasis; onset may be slower for other indications. |
| Duration of Action | Applied twice daily; clinical improvement seen within 2 weeks. |
Topical: Apply a thin film to affected areas of the scalp twice daily (morning and evening) for 2 weeks; do not exceed 50 g per week.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required; renal clearance is negligible. |
| Liver impairment | No dose adjustment required; hepatic clearance is minimal. |
| Pediatric use | Safety and efficacy in pediatric patients under 12 years have not been established; use is not recommended. |
| Geriatric use | No specific dose adjustment; use caution due to potential for skin atrophy and systemic absorption with prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUXIQ (LUXIQ).
| Breastfeeding | Topical application of corticosteroids may result in minimal systemic absorption. No data on M/P ratio for LUXIQ. Use with caution; avoid applying to breast or nipple area prior to nursing. Monitor infant for potential adrenal suppression. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for major malformations when used as directed during pregnancy. However, prolonged use of high-potency corticosteroids, especially in large amounts or on damaged skin, may increase the risk of low birth weight. No specific trimester-specific risks for LUXIQ (clobetasol propionate 0.10% foam) have been reported; however, avoid excessive use, especially in the first trimester. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to betamethasone valerate or any component of the formulation","Viral, fungal, or bacterial skin infections (unless appropriate concomitant antimicrobial therapy is administered)"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression","Local adverse reactions including atrophy, striae, telangiectasias, and acneiform eruptions","Use with caution on face, intertriginous areas, and under occlusion","Not for ophthalmic use","Pediatric patients may be more susceptible to systemic toxicity"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring required for topical use of clobetasol propionate. If used extensively or for prolonged periods, monitor maternal adrenal function and fetal growth. |
| Fertility Effects | No known adverse effects on fertility from topical corticosteroids. Systemic corticosteroids may impair fertility; however, topical use is unlikely to have significant impact. |